Intermittent everolimus administration for malignant insulinoma
Insulinoma is a rare form of insulin-secreting pancreatic islet cell neuroendocrine (NE) tumor. The medical treatment of the malignant NE disease of the pancreas deeply changed in the last years, thanks to the introduction of new target molecules, as everolimus. Even if the exact mechanism is not ac...
Main Authors: | Baratelli, Chiara, Brizzi, Maria Pia, Tampellini, Marco, Scagliotti, Giorgio Vittorio, Priola, Adriano, Terzolo, Massimo, Pia, Anna, Berruti, Alfredo |
---|---|
Format: | Online |
Language: | English |
Published: |
Bioscientifica Ltd
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174591/ |
Similar Items
-
FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report
by: Clizia Zichi, et al.
Published: (2018-04-01) -
Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature
by: Brizzi, Maria Pia, et al.
Published: (2015) -
Giant malignant insulinoma
by: Karavias, Dimitrios, et al.
Published: (2015) -
A Case of Inoperable Malignant Insulinoma with Resistant Hypoglycemia Who Experienced the Most Significant Clinical Improvement with Everolimus
by: Bozkirli, Emre, et al.
Published: (2013) -
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
by: Berruti, Alfredo, et al.
Published: (2014)